PMEF
ANIK icon

Point72 Middle East FZE’s Anika Therapeutics ANIK Stock Holding History

Point72 Middle East FZE’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,260
Closed -$73.9K – 98
2023
Q4 		$73.9K Buy
3,260
+7
+0.2% +$145 ﹤0.01% 1233
2023
Q3 		$60.6K Buy
+3,253
New +$67.5K ﹤0.01% 1218

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return

Point72 Middle East FZE's ANIK Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Anika Therapeutics (ANIK) in Q1 2024, closing a stake of 3,260 shares — an estimated $73.9K sold.

Point72 Middle East FZE first reported a position in ANIK in Q3 2023 and held it in 2 quarters. The position peaked at $73.9K in Q4 2023. 120 funds tracked by Wall St. Rank hold ANIK as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Anika Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 3,260 Anika Therapeutics shares in Q1 2024, an estimated $73.9K.
  • Point72 Middle East FZE first reported a position in Anika Therapeutics in Q3 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Anika Therapeutics position peaked at $73.9K in Q4 2023.
  • 120 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.